Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY) Sees Large Increase in Short Interest

Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY) saw a large increase in short interest in September. As of September 30th, there was short interest totaling 81,750 shares, an increase of 58.7% from the September 15th total of 51,519 shares. Based on an average daily trading volume, of 438,330 shares, the short-interest ratio is currently 0.2 days. Currently, 0.0% of the shares of the stock are sold short.

Wall Street Analysts Forecast Growth

Several analysts recently commented on CHGCY shares. UBS Group cut Chugai Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 6th. Nomura upgraded Chugai Pharmaceutical to a “hold” rating in a report on Tuesday, September 1st. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy”.

Chugai Pharmaceutical Price Performance

Shares of OTCMKTS CHGCY opened at $19.97 on Friday. The company has a market cap of $65.73 billion, a price-to-earnings ratio of 20.91 and a beta of 0.60. The stock’s 50-day moving average is $20.94 and its two-hundred day moving average is $23.17. Chugai Pharmaceutical has a 1-year low of $18.33 and a 1-year high of $34.84.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last issued its earnings results on Friday, July 24th. The company reported $0.22 earnings per share for the quarter. The firm had revenue of $2.14 billion for the quarter, compared to analysts’ expectations of $2.38 billion. Chugai Pharmaceutical had a net margin of 35.09% and a return on equity of 23.76%. Equities research analysts anticipate that Chugai Pharmaceutical will post 0.96 earnings per share for the current fiscal year.

About Chugai Pharmaceutical

Chugai Pharmaceutical Co, Ltd. is a Japan-based research-driven pharmaceutical company that develops, manufactures and markets prescription medicines. Its research focuses on oncology, immunology, neuroscience, hematology and other areas of significant unmet medical need, with capabilities spanning drug discovery, clinical development, manufacturing and commercialization.

Chugai’s portfolio includes medicines such as Actemra (tocilizumab), an immunology treatment; Hemlibra (emicizumab), used to prevent bleeding in people with hemophilia A; and Alecensa (alectinib), a targeted therapy for certain forms of lung cancer.